Read this article in Français Deutsch Italiano Português Español
Lilly to invest US$5bn in new US manufacturing facility
19 September 2025
US-based pharmaceutical company Eli Lilly has announced plans to build a US$5 billion manufacturing facility in Virginia, US, which is expected to create about 1,800 construction jobs.
Render of the Eli Lilly manufacturing facility set for construction in Virginia, US. Image: Eli Lilly
The site, west of Richmond, will be Lilly’s first fully integrated US facility for producing active pharmaceutical ingredients and drug products tied to its bioconjugate platform and monoclonal antibody portfolio.
It will also expand domestic production of antibody-drug conjugates, targeted therapies used in cancer and autoimmune treatments.
Lilly said the plant will integrate automation, AI and machine learning systems
Construction is expected to take five years.
The plant is the first of four new US sites Lilly plans to announce this year, part of $50 billion in domestic capital commitments since 2020.
STAY CONNECTED
Receive the information you need when you need it through our world-leading magazines, newsletters and daily briefings.
CONNECT WITH THE TEAM
